“And staples stocks aren’t resigned to their fate. Yardeni notes that they’re revamping their product lineup and making acquisitions to make themselves more relevant. He cites Colgate-Palmolive (CL) and Procter & Gamble (PG), which have made deals in the professional skin-care and consumer-health businesses, respectively, that look to add faster-growing or wider-margin divisions to their portfolio,” according to Barron’s.

Investors have pulled $1.04 billion from XLP since the start of the second quarter.

Rivals to XLP include the Vanguard Consumer Staples ETF (NYSEArca: VDC) and the Fidelity MSCI Consumer Staples Index ETF (NYSEArca: FSTA).

For more information on the consumer sector, visit our consumer staples category.